Introduction
This issue of Oncogene is dedicated to reviews on the topic of`chromatin remodeling'. The core chapters describe how a knowledge of the role of chromatin, coactivators and corepressors in chromatin remodeling can potentially identify the steps involved in tumorigenesis (Rietveld et al., 2001; Ferriera et al., 2001; Zhang and Dean, 2001; Robertson, 2001; Roundtree et al., 2001; Wade, 2001; Minucci et al., 2001; Pandol®, 2001) . These reviews are preceded by chapters that serve to describe various processes and enzymologies that constitute the`chromatin remodeling' ®eld. Practically all of the reviews focus on work with mammalian systems. This is a deliberate decision, since with the completion of the human genome sequence it is probable that the focus of future eorts in this ®eld will lie in understanding the basic molecular mechanisms of human disease.
Chromatin
All of the human genome is packaged into chromatin. Although chromatin was historically thought of as an inert repressive structure, we now know that it is truly a living vibrant entity. Chromatin is continually remodeled. The fundamental subunits of chromatin are the nucleosome and chromatin ®ber. The laboratory of Pierre Chambon was the ®rst to name the nucleosome (Germond et al., 1975) . Four core histones H2A, H2B, H3 and H4 serve to wrap DNA into nucleosomes. A linker histone H1 directs the path of DNA between the adjacent nucleosomes that make up the chromatin ®ber (Wole, 1998) . The nucleus, nuclear compartments, even the most fundamental subunits of the chromosome: the nucleosome and chromatin ®ber are in a continual state of¯ux. (Urnov and Wole, 2001) . It has become clear that targeted chromatin remodeling determines transcriptional control in a natural chromosomal context. Modi®cation of chromatin components also has a regulatory function in chromosomal segregation, replication, recombination and repair. These diverse processes are correlated with speci®c histone modi®cations, which are themselves dynamic (Waterborg, 2000) .
Histone acetylation renders chromatin accessible to DNA binding proteins incrementally by destabilizing the nucleosome and chromatin ®ber (Lee et al., 1993; Vetesse-Dadey et al., 1996; Tse et al., 1998) . Chromatin enriched in acetylated histones is more eciently transcribed (Ura et al., 1997; Nightingale et al., 1998) This increased gene activity could be due to an increase in the accessibility of acetylated chromatin or may follow from the direct recognition of acetylated histones by the transcriptional machinery. Although the topic of much speculation, this latter possibility is yet to be demonstrated in the context of either a nucleosome or a chromatin ®ber. These modi®cations can be targeted to a few nucleosomes, they can encompass entire chromosome domains or indeed be general to all chromosomes at particular stages of the cell cycle (Hebbes et al., 1988; Hans and Dimitrov, 2001) .
Histones are not the only substrates for posttranslational modi®cation (Imhof et al., 1997) . In certain instances the histones can be modi®ed by transcriptional activators in ways that are undetectable in vivo (Stallcup, 2001) . The diverse modi®cations of the histones and other components of the transcriptional machinery have functional and structural consequences that are still very incompletely understood (Berger, 2001 ). Targeting chromatin remodeling to speci®c promoters Among the best studied chromosomal DNA on which chromatin remodeling occurs is that containing the mouse mammary tumor virus long terminal repeats. This segment of DNA is assembled into positioned nucleosomes in vivo and in vitro (Richard-Foy and Hager, 1987; Perlmann and Wrange, 1988) . This well de®ned template is then the focus of a concerted recruitment of regulatory complexes by the glucocorticoid receptor (Grange et al., 2001; Deroo and Archer, 2001) . The relatively precise organization of recognition elements for transcription factors within the nucleosomal template points to the speci®c roles of chromatin architecture in gene activation and repression. The successful remodeling of this structure as detected by dierent nuclease and antibody probes illustrates the multitude of events that are necessary to regulate transcription in a chromosome and the high level of adaptation the transcriptional machinery has to make use of chromatin to control genes. These events can be reconstituted in vitro using a variety of extracts and puri®ed enzymes (Dilworth and Chambon, 2001 ). These approaches provide simple assays for dissecting the activities of the diverse protein complexes capable of contributing to chromatin remodeling.
Chromatin remodeling machines
The genetics of model organisms such as Drosophila melanogaster and Saccharomyces cerevisiae have led to the identi®cation of chromosomal proteins and complexes that activate or repress genes through their capacity to interact with histones and chromatin. The trithorax class of genes generally encode transcriptional activators while the Polycomb class of genes encode transcriptional repressors (Mahmoudi and Verrijzer, 2001) . Mutations in these genes contribute directly to tumorigenesis. The SWI/SNF family of yeast genes were originally identi®ed by their capacity to regulate the switching of yeast mating type (Herskowitz et al., 1992) . Homologs in mammalian cells are essential for embryonic development and tumor suppression (Muchardt and Yaniv, 2001) .
Mutations in the core histone proteins relieve the requirement for the SWI/SNF genes in yeast (Kruger et al., 1995) indicative of a direct role of the SWI/SNF genes in remodeling histone ± DNA interactions. Exactly how the SWI/SNF ATPases work to remodel chromatin remains unknown, however several viable models have been proposed most of which involve an increase in nucleosome mobility (Varga-Weisz, 2001 ). The capacity of nucleosomes to slide relative to DNA sequence provides a window of opportunity for transcriptional regulators to bind to activate or repress genes (Ura et al., 1995) . The SWI/SNF enzymes represent one category of ATPases that disrupt histone ± DNA interactions, a second class of enymes that displace histone ± DNA contacts are the DNA and RNA polymerases. Nucleosomes and transcription complexes are disrupted by replication fork progression (Sogo et al., 1986; Wole and Brown, 1986) . The ensuing competition provides a window of opportunity for the reprogramming of states of gene activity (Demeret et al., 2001; Barton and Crowe, 2001 ).
Chromatin and cancer
Cancer can occur when essential regulatory proteins are altered so that development stops while cells can still divide. An example of this type of carcinogenic process is the ability of avian erythroblastosis virus to subvert the normal functional properties of the thyroid hormone receptor (TR) by introducing a mutant form of the receptor as the oncoprotein v-ErbA. The TR directs the dierentiation of chicken blood cells through the targeting of chromatin remodeling machinery including histone acetyltransferases to particular chromosomal sites. In contrast to the thyroid receptor, v-ErbA cannot bind to thyroid hormone, as a consequence of which it can no longer recruit histone acetyltransferases. Instead v-ErbA constitutively recruits histone deacetylase to block the specialized cell functions that occur in a normal dierentiated blood cell. This promotes the proliferation of these cells to cause leukemia (Rietveld et al., 2001) .
In humans, a similar misuse of histone deacetylase leads to the uncontrolled proliferation of immature blood cells known as myelocytes and to acute myeloid leukemia (AML) and acute promyelocytic leukemia (PML). Both of these disorders are associated with chromosomal translocations. In AML, the key gene that is disrupted encodes a transcription factor, AML-1 that is important in the control of myeloid-speci®c gene expression. In the chromosomal translocation the DNA binding domain of AML-1 is fused to a protein known as ETO, which interacts with a histone deacetylase. Repression of cell dierentiation by the AML-1 targeted histone deacetylase contributes to leukemia (Minucci et al., 2001) . In PML, a comparable chromosomal translocation results in the fusion of PML to a portion of the retinoic acid receptor (RAR) that recruits histone deacetylase. Again this leads to a failure of the myelocytes to dierentiate, and leukemia results. In the PML-RAR fusion protein, the capacity to bind trans-retinoic acid is retained. Addition of trans-retinoic acid leads to a comformational change in PML-RAR and the release of histone deacetylase. This hormone dependent`dierentiation therapy' can lead to remission of the leukemia. More recently histone deacetylase inhibitors have been used directly for therapy (Pandol®, 2001) . This approach to treat the enzymes of chromatin remodeling as`druggable' targets for therapeutic intervention provides a whole new area for the pharmaceutical industry to explore.
Elements of the major controlling pathways of the cell cycle are often mutated in many human cancers. These include the cyclin dependent kinase inhibitors p16/ink4A and the retinoblastoma (Rb) protein. The p16 and Rb genes are also often silenced by DNA methylation. Rb functions by the recruitment of the human homologs of the SWI/SNF enzymes BRG1 (Zhang and Dean, 2001) , histone deacetylase (Ferreira et al., 2001) and DNA methyltransferase (Robertson, 2001) . Thus a key checkpoint protein depends on chromatin remodeling to silence genes that would otherwise drive continued cell proliferation. The association of histone deacetylase with DNA methyltransferase provides a pathway by which the establishment of silent heterochromatin and enrichment in histone deacetylase might drive the subsequent recruitment of DNA methyltransferase (Robertson, 2001; Rountree et al., 2001) . DNA methylation itself will serve to recruit histone deacetylase through the action of the Mi-2 and MeCP2 ± SIN3 complexes that contain methyl CpG binding proteins (Wade, 2001) . The recognition and selective inhibition of these chromatin remodeling pathways may oer another exciting therapeutic window in cancer biology.
Perspective
The most signi®cant aspect of the cancer-chromatin connection is the recognition that the expression of key genes required to convert a normal cell to a cancer cell relies on enzymes. By alternately acetylating or deacetylating histones in the context of ATP ± driven chromatin remodeling, the accessibility and transcriptional competence of a gene can be determined. Much of the pathological gene silencing that occurs in cancer is a consequence of the mistargeting of these enzymes. This may make pathologically silenced genes uniquely susceptible to drugs that inhibit these enzymes. Selective reactivation of these genes may occur because the redundant pathways that serve to repress a gene in a normal developmental process are lost in a gene silenced by the AML ± ETO oncoprotein, or by aberrant DNA methylation. The future oers the prospect of designing pharmaceuticals or unique engineered transcription factors (Pandol®, 2001; Zhang et al., 2000; Liu et al., 2000) with the exquisite speci®city necessary to interfere with individual histone deacetylases or SWI/SNF ATPases with direct therapeutic consequences on the misregulated transcription pathway in a particular tumor type.
